Crossref journal-article
Society for Neuroscience
The Journal of Neuroscience (393)
Abstract

Hypoxia is the most common cause of perinatal seizures and can be refractory to conventional anticonvulsant drugs, suggesting an age-specific form of epileptogenesis. A model of hypoxia-induced seizures in immature rats reveals that seizures result in immediate activation of the phosphatase calcineurin (CaN) in area CA1 of hippocampus. After seizures, CA1 pyramidal neurons exhibit a downregulation of GABAAreceptor (GABAAR)-mediated inhibition that was reversed by CaN inhibitors. CaN activation appears to be dependent on seizure-induced activation of Ca2+-permeable AMPA receptors (AMPARs), because the upregulation of CaN activation and GABAAR inhibition were attenuated by GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride] or Joro spider toxin. GABAAR β2/3 subunit protein was dephosphorylated at 1 h after seizures, suggesting this subunit as a possible substrate of CaN in this model. Finally,in vivoadministration of the CaN inhibitor FK-506 significantly suppressed hypoxic seizures, and posttreatment with NBQX (2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline) or FK-506 blocked the hypoxic seizure-induced increase in CaN expression. These data suggest that Ca2+-permeable AMPARs and CaN regulate inhibitory synaptic transmission in a novel plasticity pathway that may play a role in epileptogenesis in the immature brain.

Bibliography

Sanchez, R. M., Dai, W., Levada, R. E., Lippman, J. J., & Jensen, F. E. (2005). AMPA/Kainate Receptor-Mediated Downregulation of GABAergic Synaptic Transmission by Calcineurin after Seizures in the Developing Rat Brain. The Journal of Neuroscience, 25(13), 3442–3451.

Authors 5
  1. Russell M. Sanchez (first)
  2. Weimin Dai (additional)
  3. Rachel E. Levada (additional)
  4. Jocelyn J. Lippman (additional)
  5. Frances E. Jensen (additional)
References 53 Referenced 89
  1. 10.1111/j.1528-1157.1984.tb04168.x / Epilepsia (1984)
  2. 10.1016/S0031-3955(16)38846-0 / Pediatr Clin North Am (1994)
  3. 10.1016/S0006-8993(99)02100-9
  4. 10.1523/JNEUROSCI.19-21-09228.1999 / J Neurosci (1999)
  5. 10.1074/jbc.M004910200
  6. 10.1016/S0028-3908(01)00135-6
  7. 10.1097/00005072-199904000-00007
  8. 10.1113/jphysiol.1995.sp020522 / J Physiol (Lond) (1995)
  9. 10.1097/00001756-200011090-00035 / NeuroReport (2000)
  10. 10.1016/S0006-8993(00)02623-8
  11. 10.1074/jbc.274.51.36565
  12. 10.1038/sj.bjp.0702236
  13. 10.1016/S0006-8993(01)03308-X
  14. 10.1111/j.1471-4159.1993.tb07465.x
  15. 10.1016/S0021-9258(19)39919-3 / J Biol Chem (1990)
  16. {'key': '2023041303115101000_25.13.3442.16', 'first-page': '243', 'volume': '286', 'year': '1998', 'journal-title': 'J Pharmacol Exp Ther'} / J Pharmacol Exp Ther (1998)
  17. 10.1002/(SICI)1098-2779(1997)3:1<85::AID-MRDD11>3.0.CO;2-N / Mental Retard Dev Disabil Res Rev (1997)
  18. 10.1002/ana.410290610
  19. 10.1111/j.1528-1157.1992.tb01746.x
  20. 10.1111/j.1528-1157.1995.tb00954.x
  21. 10.1152/jn.1998.79.1.73 / J Neurophysiol (1998)
  22. 10.1523/JNEUROSCI.17-20-07626.1997 / J Neurosci (1997)
  23. 10.1016/S0306-4522(99)00462-5
  24. 10.1113/jphysiol.1995.sp020813 / J Physiol (Lond) (1995)
  25. 10.1002/ana.1122
  26. 10.1111/j.0013-9580.2004.69103.x
  27. 10.1016/0896-6273(94)90316-6
  28. 10.1523/JNEUROSCI.22-08-03005.2002 / J Neurosci (2002)
  29. 10.1046/j.1471-4159.2001.00426.x
  30. {'key': '2023041303115101000_25.13.3442.30', 'first-page': '558', 'volume': '27', 'year': '2001', 'journal-title': 'Soc Neurosci Abstr'} / Soc Neurosci Abstr (2001)
  31. 10.1016/S0896-6273(00)81150-2
  32. 10.1038/223
  33. 10.1152/jn.2000.83.1.50 / J Neurophysiol (2000)
  34. 10.1016/S0301-0082(98)00073-2
  35. 10.1126/science.1323140
  36. 10.1046/j.1471-4159.2002.00876.x
  37. 10.1056/NEJM199908123410704
  38. 10.1016/S0021-9258(18)32091-X / J Biol Chem (1983)
  39. 10.1016/S0006-8993(02)03578-3
  40. 10.1002/jnr.10472
  41. 10.1046/j.1528-1157.2001.12000.x
  42. 10.1523/JNEUROSCI.21-20-08154.2001 / J Neurosci (2001)
  43. 10.1016/S0896-6273(00)00089-1
  44. 10.1093/oxfordjournals.jbchem.a003063
  45. 10.1016/S0896-6273(00)80538-3
  46. 10.1016/S0165-6147(97)01146-2
  47. 10.1073/pnas.92.14.6269
  48. 10.1016/S0028-3908(00)00213-6
  49. 10.1002/(SICI)1098-1063(1998)8:6<566::AID-HIPO2>3.0.CO;2-W
  50. 10.1002/1098-2779(200102)7:1<56::AID-MRDD1008>3.0.CO;2-A / Mental Retard Dev Disabil Res Rev (2001)
  51. 10.1016/j.neuroscience.2004.05.056
  52. 10.1016/S0022-510X(00)00386-5
  53. 10.1016/S0165-6147(97)01046-8
Dates
Type When
Created 20 years, 4 months ago (March 30, 2005, 4:03 p.m.)
Deposited 2 years, 4 months ago (April 13, 2023, 12:38 p.m.)
Indexed 3 weeks, 1 day ago (Aug. 7, 2025, 4:54 a.m.)
Issued 20 years, 4 months ago (March 30, 2005)
Published 20 years, 4 months ago (March 30, 2005)
Published Online 20 years, 4 months ago (March 30, 2005)
Published Print 20 years, 4 months ago (March 30, 2005)
Funders 0

None

@article{Sanchez_2005, title={AMPA/Kainate Receptor-Mediated Downregulation of GABAergic Synaptic Transmission by Calcineurin after Seizures in the Developing Rat Brain}, volume={25}, ISSN={1529-2401}, url={http://dx.doi.org/10.1523/jneurosci.0204-05.2005}, DOI={10.1523/jneurosci.0204-05.2005}, number={13}, journal={The Journal of Neuroscience}, publisher={Society for Neuroscience}, author={Sanchez, Russell M. and Dai, Weimin and Levada, Rachel E. and Lippman, Jocelyn J. and Jensen, Frances E.}, year={2005}, month=mar, pages={3442–3451} }